learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forProducts matching "psk-3841"
Tracking 1 products like 265 RU-58841 Solution 50mg/ml – 50ml from by companies like Chemyo. View product »Learn
5 / 801 resultslearn TDM-105795
learn KX-826
learn Peach Kernel
learn EUK 134
Research
5 / 1000+ resultsresearch A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research A multi-centre, double-blind, randomised, vehicle-controlled study for a quantitative estimation of hair re-growth in male subjects with androgenetic alopecia treated over 6 month with two ethanolic PSK 3841 solutions (2.5% and 5%)
research Investigational medications in the treatment of alopecia
New treatments for hair loss are being developed using molecular biology.
research Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism
Hair loss treatments include medications and new methods like low-level light therapy, which may work by boosting cell activity and blood flow.
research Experimental and early investigational drugs for androgenetic alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
Community Join
5 / 13 resultscommunity The story of RU58841 / PSK 3841
RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community I spoke to the Guy who did the Ru58841 (PSK-3841) research
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
community Research about RU58841 /Why it was stopped
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.